CERE News and Press, Ceres Inc. From 04/18/24

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to ...

2024-04-04 15:12:29 ET More on AbbVie AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Aldeyra gains as Oppenheime...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...

2024-03-19 01:45:00 ET Summary Companies are taking advantage of strong investor demand in the investment grade credit market. In just the first two months of 2024, we’ve seen nearly 200 companies issue roughly $380 billion of new bonds in the U.S. investment grade credit p...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

2024-03-11 19:11:51 ET Summary Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major Depressive Disorder. CAPLYTA's growing acceptan...

2024-03-11 08:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....